tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: Axonics Modulation Technologies (AXNX), Innate Pharma (IPHA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axonics Modulation Technologies (AXNXResearch Report) and Innate Pharma (IPHAResearch Report) with bullish sentiments.

Axonics Modulation Technologies (AXNX)

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Buy rating on Axonics Modulation Technologies, with a price target of $80.00. The company’s shares closed last Tuesday at $70.94.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 19.9% and a 50.7% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Irhythm Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axonics Modulation Technologies with a $80.86 average price target, which is a 21.1% upside from current levels. In a report issued on July 20, Truist Financial also maintained a Buy rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

Innate Pharma (IPHA)

SVB Securities analyst Daina Graybosch maintained a Buy rating on Innate Pharma today and set a price target of $10.00. The company’s shares closed last Tuesday at $2.77, close to its 52-week low of $2.00.

According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 29.5% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Century Therapeutics, and Bolt Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innate Pharma with a $8.25 average price target, which is a 207.8% upside from current levels. In a report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $5.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AXNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More